slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
214,021-214,050 of 319,975
24
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
25
Includes scientific diagrams of molecular pathways and efficacy data charts.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
26
Layout splits into three quadrants of charts (survival %, tumor response %, median survival days) plus a navy summary band; Immix Biopharma logo top-right and page number 26 bottom-right.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
27
Includes a process diagram showing the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
28
Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor growth.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
29
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
30
Includes waterfall and spider/line charts for clinical efficacy. Source note at bottom.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
31
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
32
The chart visualizes a single data point (4 months mPFS at 100% of patients with >=3 prior lines of therapy) as a highlighted marker.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
33
Shows two parallel tracks: monotherapy and combination therapy with tislelizumab.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
34
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
35
The slide uses a process-flow style layout to connect platform capabilities to specific drug candidates.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
36
The slide uses a '3 Pillars' framework to explain the platform's foundation, leading into specific product applications.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
37
Includes technical diagrams of the drug structure, bar charts for expression, and a Kaplan-Meier survival curve.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
38
Includes two sets of charts: tumor volume over time and survival curves for MDA-MB-231 and HCT-116 models.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
39
Includes multiple scientific diagrams and clinical trial data summaries.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
40
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
41
The slide is divided into two sections: ImmixBio Clinical Advisory Board (top) and Selected Nexcella Scientific Advisory Board Members (bottom).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
42
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
43
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
44
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
45
The slide uses a bar chart to contrast the combined sales of two groups of oncology drugs ($33.4bn vs $0.9bn).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
46
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo, likely to frame the market opportunity for IMX-120.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
01
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
03
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
04
The slide uses a wave-like visual to represent market segments and their associated financial opportunities.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
05
The slide highlights NXC-201's superior efficacy (100% response rate) and safety profile (zero neurotoxicity) compared to existing therapies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
06
The slide explicitly notes that these are cross-trial comparisons and not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
07
The slide uses a table structure to contrast standard of care with the company's target segment. The bottom section uses bar charts to imply relative patient population growth.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit